
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies is on track for continued growth with their strong performance in the MRD market, increased testing in community settings, and partnerships with pharmaceutical companies. Their plan to separate their MRD business and negotiate higher prices with health plans adds further potential for revenue and margin growth. While there are uncertainties with the separation, overall the company shows promising potential for long-term success and a BUY rating is warranted at this time.
Bears say
Adaptive Biotechnologies is facing key risks in the near future, including slower EMR integrations and increasing competition in the heme market, which could impede volume growth and strain resources for its MRD segment. Additionally, there are stock market risks and ADPT trades at a premium multiple, making it susceptible to volatility. While they have a strong position in the MRD market and continued profitability, there is uncertainty around stock reactions and future catalysts.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares